<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20090203001640N16</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-01-13</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>ٍEvaluation of substitution of animal proteins with plant proteins in DASH diet  in obese individuals with metabolic syndrome</public_title>
      <acronym></acronym>
      <scientific_title>effect of substitution of animal proteins with plant proteins in DASH diet on glycemic indicators, lipid profile, Apo lipoproteins, Blood pressure and  anthropometric indicators in obese individuals with metabolic syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39057</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This parallel-group randomized clinical trial will be conducted at Research Institute for Endocrine Sciences, SBMU, Tehran, Iran. In this study, patients will be divided into two groups [intervention(DASH diet containing 2/3 plant proteins and 1/3 animal proteins)] and control (DASH diet containing 2/3 animal protein and 1/3 plant proteins) by using random sequence. The allocation ratio will be 1:1. For randomly assignment of patients to the two groups, stratified blocked randomization method will be used.The division of the strata is based on the sexuality so that patients are first classified into men and women groups. After specifying four blocks in different layouts random selection approach will be used to set the allocation of treatment. the allocation of both groups will be concealed from main researcher in the biochemical laboratories and statistician who will analyze the data and the codes that will be placed to the packets will be available to the researchers for random sampling, Blinding description: This study is designed as a double blind study. The main researcher and patients are not aware which DASH diet group contains 2/3 plant proteins or 2/3 animal proteins, and the main investigator is not involved in the randomization process.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: metabolic syndrome. Condition 2: obesity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: DASH diet including 15% protein, 30% fat and 55% carbohydrate with intake of 2/3 proteins need from plant proteins( contain grains, nuts or seeds and legumes) and 1/3 animal proteins( contain milk, meat, cheese and eggs). Intervention 2: Control group: DASH diet including 15% protein, 30% fat and 55% carbohydrate with intake of 1/3 proteins need from plant proteins( contain grains, nuts or seeds and legumes) and 2/3 animal proteins( contain milk, meat, cheese and eggs).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is there is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Hasan Vasei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.46, Arghavan-E-Gharbi St., Farahzadi Blv., Shahrak-E-Ghods</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>193954741</zip>
        <telephone>+98 21 2235 7484</telephone>
        <email>Ehsanvasei21@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Hasan Vasei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 46, Arghavan-E-Gharbi St., Farahzadi Blv., Shahrak-E-Ghods</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>193954741</zip>
        <telephone>+98 21 2235 7484</telephone>
        <email>Ehsanvasei21@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Agreement to participate in the study and completing informed consent form
aged 30-70 years old
No change in weight over the past 3 months
body mass index: 25-40
having Metabolic syndrome
Not having special diet
Non-pregnancy and lactation</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy and Lactation,  having liver disease (non-alcoholic fatty liver Grade 3), kidney disease (GFR &lt;60 ml / min / 1.73 m2), gastrointestinal disease, allergy.
Use of effective drugs in weight loss
Unwilling to consume legumes and nuts in the diet</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E88.81</hc_code>
      <hc_code>E66.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>metabolic syndrome</hc_keyword>
      <hc_keyword>Obesity due to excess calories</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: DASH diet including 15% protein, 30% fat and 55% carbohydrate with intake of 2/3 proteins need from plant proteins( contain grains, nuts or seeds and legumes) and 1/3 animal proteins( contain milk, meat, cheese and eggs)</i_keyword>
      <i_keyword>Control group: DASH diet including 15% protein, 30% fat and 55% carbohydrate with intake of 1/3 proteins need from plant proteins( contain grains, nuts or seeds and legumes) and 2/3 animal proteins( contain milk, meat, cheese and eggs)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum concentration of blood glucose. Timepoint: befor the intervention and 8 weeks after intervention. Method of measurement: enzymatic method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Serum concentration of total cholesterol. Timepoint: before the intervention and 8 weeks after intervention. Method of measurement: enzymatic method.</sec_outcome>
      <sec_outcome>Serum concentrations of triglyceride. Timepoint: before the intervention and 8 weeks after intervention. Method of measurement: enzymatic method.</sec_outcome>
      <sec_outcome>Low density lipoprotein- cholesterol. Timepoint: before the intervention and 8 weeks after intervention. Method of measurement: enzymatic method.</sec_outcome>
      <sec_outcome>High density lipoprotein- cholesterol. Timepoint: before the intervention, 8 weeks after intervention. Method of measurement: enzymatic method.</sec_outcome>
      <sec_outcome>Serum concentration of Apolipoprotein- A1. Timepoint: before the intervention and 8 weeks after intervention. Method of measurement: enzymatic method.</sec_outcome>
      <sec_outcome>Serum concentration of apolipoprotein- B. Timepoint: before the intervention and 8 weeks after intervention. Method of measurement: enzymatic method.</sec_outcome>
      <sec_outcome>Height. Timepoint: before the intervention and 8 weeks after intervention. Method of measurement: stadiometer.</sec_outcome>
      <sec_outcome>Weight. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: Seca scale.</sec_outcome>
      <sec_outcome>Blood pressure. Timepoint: before the intervention and 8 weeks after intervention. Method of measurement: Mercury barometer.</sec_outcome>
      <sec_outcome>Waist circumference. Timepoint: before the intervention and 8 weeks after intervention. Method of measurement: tape meter.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for Research, Institute of Nutrition and Food Industry of Iran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-06-19</approval_date>
        <contact_name>ethics committee of national nutrition and food technology research institute</contact_name>
        <contact_address>No. 7, Shahid Farahzadi Blvd, Shahid Hafezi Street (West Arghavan), Qods Town (West), Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
